INVEST SECURITIES - Ose Immunotherapeutics : 3 « nouvelles » études lancées en 2018 - ACHAT, OC : 8€
Après une année 2017 à moult rebondissements, nous y voyons plus clair en ce début d'année. La reprise de l'étude évaluant Tedopi dans le cancer du poumon non à petites cellules a été validée par la société et les autorités de santé américaine : une première étape recrutant 100 patients avec des résultats prévus courant 2020, et une seconde étape qui sera à définir au vu de ces résultats (extension ou non de l'essai). En parallèle, les deux partenariats signés avec Janssen et Servier suivent leurs cours avec l'entrée cette année de FR104 en phase II et OSE 127 en phase I. Nous maintenons notre recommandation à ACHAT.Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.